镰状细胞病
镰状细胞病是一种常见且危及生命的血液系统疾病,影响全球数百万人。异常镰状红细胞阻塞小血管,导致远端组织缺血和炎症,引发急性疼痛性镰状细胞危象。反复镰变和溶血性贫血导致实质器官损伤和慢性器官损害,造成显著发病率和早期死亡。现有治疗限于输血和羟基脲,干细胞移植可能为潜在治愈手段,基因治疗和基因编辑等新疗法正在开发中。
要点
- 异常镰状红细胞阻塞小血管,导致组织缺血和炎症,引发急性疼痛性镰状细胞危象。
- 反复镰变和溶血性贫血导致实质器官损伤和慢性器官损害,造成显著发病率和早期死亡。
- 现有治疗限于输血和羟基脲,干细胞移植可能为潜在治愈手段,基因治疗和基因编辑等新疗法正在开发中。
核心结论
- 镰状细胞病是一种常见且危及生命的血液系统疾病,异常镰状红细胞阻塞小血管导致组织缺血和炎症,反复镰变和溶血性贫血导致器官损伤和早期死亡。
- 现有治疗限于输血和羟基脲,干细胞移植可能为潜在治愈手段,基因治疗和基因编辑等新疗法正在开发中。
主要发现
- 异常镰状红细胞阻塞小血管,导致远端组织缺血和炎症,引发急性疼痛性镰状细胞危象。
- 反复镰变和持续溶血性贫血,即使亚临床,也导致实质器官损伤和慢性器官损害,造成显著发病率和早期死亡。
- 近期进展包括卒中风险的系统性普遍筛查、使用口服螯合剂和非侵入性MRI测量改善铁过载管理,以及即时诊断设备。
局限性
- 争议包括溶血在镰状细胞病病理生理学中的作用、妊娠的最佳管理以及预防脑血管疾病的策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Sickle cell disease is a common and life-threatening haematological disorder that affects millions of people worldwide. Abnormal sickle-shaped erythrocytes disrupt blood flow in small vessels, and this vaso-occlusion leads to distal tissue ischaemia and inflammation, with symptoms defining the acute painful sickle-cell crisis. Repeated sickling and ongoing haemolytic anaemia, even when subclinical, lead to parenchymal injury and chronic organ damage, causing substantial morbidity and early mortality. Currently available treatments are limited to transfusions and hydroxycarbamide, although stem cell transplantation might be a potentially curative therapy. Several new therapeutic options are in development, including gene therapy and gene editing. Recent advances include systematic universal screening for stroke risk, improved management of iron overload using oral chelators and non-invasive MRI measurements, and point-of-care diagnostic devices. Controversies include the role of haemolysis in sickle cell disease pathophysiology, optimal management of pregnancy, and strategies to prevent cerebrovascular disease.
引用
- Ware RE, de Montalembert M, Tshilolo L, et al. Sickle cell disease. Lancet. 2017. PMID: 28159390. doi:10.1016/S0140-6736(17)30193-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。